RecruitingNCT07342231

FAPi PET in Pancreatic Ductal Adenocarcinoma

FAP-1 Study: FAPi PET in Pancreatic Ductal Adenocarcinoma: A Prospective, Exploratory Study


Sponsor

Tata Memorial Hospital

Enrollment

60 participants

Start Date

Jan 4, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Pancreatic adenocarcinoma commonly referred to as pancreatic cancer is a cancer which is known to involve the pancreas and the surrounding structures like blood vessels, which makes it an aggressive cancer. Treatment of the cancer is decided by how much the disease has spread. It has been understood from recent studies that there are some components of the tumor which are not detected by standard CT scan. The tissue in the tumor microenvironment leads to further spread of tumor. The tissue which is seen near the tumor has many attachments on the surface which are currently being studied. One of the most common attachments is Fibroblast activation protein (FAP), which is seen on the surface of tumor tissue. A radioactive tracer Gallium-68 is attached to a small protein known as 'peptide' named 'FAP inhibitor (FAPi)' which shall bind to FAP. Then a PET scan will be performed which shall help in understanding how much of the tissue is seen on the scan in addition to the pancreatic tumor. The investigators shall assess whether the radiotracer (Gallium-68 labeled FAPi) binds to other sites like liver or other organs where the cancer is likely to spread. From the study, the investigators shall study whether the new scanning technique is beneficial as compared to the standard CT scanning. Hence, the investigators would perform Gallium-68-labeled FAPi PET scan in addition to the standard CT scan and compare the results.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating whether a specialised PET scan using a tracer called FAPi (fibroblast activation protein inhibitor) can better detect and stage pancreatic cancer compared to standard CT or PET scans. Pancreatic cancer is difficult to detect early, and better imaging could improve treatment planning. **You may be eligible if...** - You are 18 or older - You have pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) confirmed by biopsy - You are willing to participate **You may NOT be eligible if...** - You have another active cancer at the same time - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTGa-68 FAPi PET/CT

Ga-68 FAPi PET/CT is a whole body scan to assess the FAP receptor expression in patients with pancreatic ductal adenocarcinoma


Locations(1)

Tata Memorial Hospital, Mumbai, India

Mumbai, Maharashtra, India

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07342231


Related Trials